Episodes

Jeff Park spent over a decade transforming SKC Health Solutions into Catamaran, a pharmacy benefits technology company that sold to UnitedHealthcare for $12.8 billion, a 65 times return on the original investment. He did it through 14 plus acquisitions, a relentless integration playbook, and one core belief: people are the only competitive advantage. In this episode of No Spotlight Needed, Jeff walks through how he earned the right to speak as a 25 year old sitting on ten boards, what the IPO t...

Some of the best conversations are with the people you think you already know. In this episode of No Spotlight Needed, host Sheetal Mehta Prasad sits down with Dipal Doshi, CEO of Entrada Therapeutics, for an honest look at what it takes to build a biotech company with conviction. Dipal was Entrada's first full-time employee. As a non-scientist, he helped take the company from an unproven hypothesis through its IPO and into active clinical development in one of the most competitive areas in bio...

On paper, SOPHiA GENETICS should not have worked. Jurgi Camblong was not a software engineer or a trained CEO. He was building an AI company in Switzerland in 2011 before AI was a mainstream conversation, raising capital in Europe when most of the money was in the United States, and selling to hospitals that needed years to trust the technology. Fifteen years later, SOPHiA GENETICS supports nearly 1000 hospital customers and has analyzed over 2.5 million genomic profiles. In this conversation, ...

Paul Perreault led CSL for a decade, growing it into a $130 billion market cap company and the world's leading manufacturer of plasma derived therapies. He started as a field sales rep, planned to become a priest, and carried one lesson through his entire career: never confuse your job title with who you are. In this conversation Paul talks about the generalist philosophy that shaped his leadership, the capital discipline that made CSL different from every other biotech, the three major acquisi...

Kevin Sayer spent 15 years as CEO of Dexcom, growing it from a niche startup into a $4 billion company that created the continuous glucose monitoring industry from scratch. In this episode of No Spotlight Needed, he sits down with Sheetal to tell the whole story: the early bets, the hard lessons, the bold moves, and what it really took to build something that has saved lives around the world. Kevin opens up about his recent cancer diagnosis and recovery, the toughest quarter of his career in 20...

What does a career look like when one chapter ends with an $11 billion acquisition, the next involves FBI visits and death threats, and the third ends with a devastating phase 3 failure that nobody saw coming?Dr. Michelle Berrey has lived all three. Over 15 years as a chief medical officer and CEO at Pharmasset, Chimerix, and Intercept Pharmaceuticals, she helped develop a cure for hepatitis C, navigated a national social media firestorm over a dying child, led a company through the Ebola outbre...

What does it actually take to build a biotech from nothing... no IP, no programs, no money — into a company acquired by Eli Lilly for over $3 billion? In this episode of No Spotlight Needed, host Sheetal sits down with Praveen Tipirneni — engineer, physician, and military-trained biotech CEO who built Morphic Therapeutic over nine years, nearly died from an out-of-hospital cardiac arrest midway through, and still came back to close one of biotech's biggest deals of 2024. Now he's doing it again...

Welcome to Season 2 of No Spotlight Needed! Episode 1 features Bruce Cozadd, former CEO of Jazz Pharmaceuticals. Bruce walks through the real moments behind building Jazz into a durable business, including what happened during the 2008 crash, how he thought about culture as the company scaled, why “bet the company” decisions need to be named out loud, and what it looks like to step away after a 20 plus year run without leaving a shadow behind. If you care about leadership, team building, and ...